Attaching an Explanation of Benefits (EOB) to Secondary Claims

When billing MaineCare secondary claims, you must attach an EOBA to all claims regardless of the submission type listed below:

  • Direct Data Entry (DDE)
  • Paper
  • Electronic Data Interchange (EDI)

When submitting electronically, upload the EOB once the claim is in MIHMS. The charges billed on the claim lines must match the charges billed on the EOB, or the claim will be denied.

Facility Licenses Under Title 5

Providers whose facility license is under a Title 5 review may use their Title 5 notice to extend their enrollment with MaineCare in MIHMS by six months, and for every six months thereafter, until the Title 5 review is resolved. Providers must complete this update by submitting a maintenance case via the Health PAS Online Portal. Providers can utilize the Provider Maintenance User Guide for a step-by-step guide for submitting a Title 5 Maintenance Case.

Annual 1115 Substance Use Disorder (SUD) Waiver Post Award Forum

On December 22, 2020, Maine DHHS announced the Center’s for Medicare & Medicaid Services (CMSs) approval of MaineCare’s waiver request, which lifts the federal restriction for residential or inpatient SUD treatment programs beyond 16 beds. The Implementation Plan was approved on July 26, 2021, which allows MaineCare to begin collecting federal funds for residential treatment facilities that expand their capacity.

MaineCare Provider Enrollment Progress Update

Gainwell continues to reduce the time it takes to complete their steps within the MaineCare enrollment process. Gainwell completed 559 enrollment cases in March and the average turnaround time for case completion was approximately 20 days. Case inventory was 578 at the end of March and the average system age of a case in inventory dropped to approximately 16.4 days old.

Additionally, to improve MaineCare enrollment, the Office of MaineCare Services (OMS) and Gainwell:

Pemgarda (pemivibart) Receives Emergency Use Authorization (EUA)

On March 22, 2024, the Food and Drug Administration (FDA) issued EUA for Pemgarda for the prevention of COVID-19 for individuals aged 12 and up with moderate to severe immune compromise due to a medical condition or taking immunosuppressive medications or treatments. These individuals are unlikely to mount an adequate immune response to COVID-19 vaccines. Pemgarda is not a substitute for COVID-19 vaccinations.

Subscribe to